ENElena Naranjo-Sánchez

Elena Naranjo-Sánchez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena Naranjo-Sánchez has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Telomerase RNA-based aptamers restore defective myelopoiesis in congenital neutropenic syndromes

    by Elena Martínez-Balsalobre, Jesús García-Castillo, Diana García-Moreno, Elena Naranjo-Sánchez, Miriam Fernández-Lajarín, María A. Blasco, Francisca Alcaraz-Pérez, Victoriano Mulero, María L. Cayuela

    Telomerase RNA (TERC) has a noncanonical function in myelopoiesis binding to a consensus DNA binding sequence and attracting RNA polymerase II (RNA Pol II), thus facilitating myeloid gene expression. The CR4/CR5 domain of TERC is known to play this role, since a mutation of this domain found in dyskeratosis congenita (DC) patients decreases its affinity for RNA Pol II, impairing its myelopoietic activity as a result. In this study, we report that two aptamers, short single-stranded oligonucleotides, based on the CR4/CR5 domain were able to increase myelopoiesis without affecting erythropoiesis in zebrafish. Mechanistically, the aptamers functioned as full terc; that is, they increased the expression of master myeloid genes, independently of endogenous terc, by interacting with RNA Pol II and with the terc-binding sequences of the regulatory regions of such genes, enforcing their transcription. Importantly, aptamers harboring the CR4/CR5 mutation that was found in DC patients failed to perform all these functions. The therapeutic potential of the aptamers for treating neutropenia was demonstrated in several preclinical models. The findings of this study have identified two potential therapeutic agents for DC and other neutropenic patients.


  • Open Access

    ZAKα/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome

    by Lola Rodríguez‐Ruiz, Juan M Lozano‐Gil, Elena Naranjo‐Sánchez, Elena Martínez‐Balsalobre, Alicia Martínez‐López, Christophe Lachaud, Miguel Blanquer, Toan K Phung, Diana García‐Moreno, María L Cayuela, et al.

    Chronic inflammatory diseases are associated with hematopoietic lineage bias, including neutrophilia and anemia. We have recently identified that the canonical inflammasome mediates the cleavage of the master erythroid transcription factor GATA1 in hematopoietic stem and progenitor cells (HSPCs). We report here that genetic inhibition of Nlrp1 resulted in reduced number of neutrophils and increased erythrocyte counts in zebrafish larvae. We also found that the NLRP1 inflammasome in human cells was inhibited by LRRFIP1 and FLII, independently of DPP9, and both inhibitors regulated hematopoiesis. Mechanistically, erythroid differentiation resulted in ribosomal stress‐induced activation of the ZAKα/P38 kinase axis which, in turn, phosphorylated and promoted the assembly of NLRP1 in both zebrafish and human. Finally, inhibition of Zaka with the FDA/EMA‐approved drug Nilotinib alleviated neutrophilia in a zebrafish model of neutrophilic inflammation and promoted erythroid differentiation and GATA1 accumulation in K562 cells. In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.


  • Topic: AS08-Treatment/AS08d-New developments – Preclinical studies: DEVELOPMENT OF APTAMERS AS THERAPY FOR CONGENITAL NEUTROPENIA DISEASES

    by M. Cayuela, J. García-Castillo, E. Martinez-Balsalobre, D. García-Moreno, E. Naranjo-Sánchez, M. Fernández-Lajarin, A. Jiménez-Blaya, F. Alcaraz-Pérez, V. Mulero